Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05121012 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Synaptic Loss in Multiple System Atrophy

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 20 to 36v5 Show 6 more changesShow less
    • Primary endpoint revised
    • Interventions: Study procedures (Other) to Study procedures for MSA patients (Other), Study procedures for PSP patients (Other)
    • Eligibility criteria expanded, about 593 words
    • Secondary endpoints: 24 to 27
    • Study description expanded, about 166 words
    • Study arms: 1 to 2
  2. Primary and study completion dates: Apr 1, 2025 to Mar 31, 2027v4
  3. Re-verified, no change to tracked fieldsv3
  4. Primary and study completion dates: Sep 1, 2024 to Apr 1, 2025
    • Secondary endpoints revised (24)
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this study the investigators would like to investigate the degree of damage of the synapses, an important part of the neurons vital for the communications between neurons, in Multiple System Atrophy (MSA), and pathology related to abnormal accumulation of a protein named tau, in Progressive Supranuclear Palsy (PSP).
Trial Details
NCT Number NCT05121012
Lead Sponsor University of Exeter
Conditions
(from sponsor)		 Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)
Related terms Multiple System Atrophy, Nerve Degeneration, Supranuclear Palsy, Progressive
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov